Challenges in the discontinuation of chronic hepatitis B antiviral agents  

作　　者：Apichat Kaewdech Pimsiri Sripongpun 

机构地区：[1]Department of Internal Medicine,Faculty of Medicine,Prince of Songkla University,Hat Yai 90110,Songkhla,Thailand

出　　处：《World Journal of Hepatology》2021年第9期1042-1057,共16页世界肝病学杂志（英文版）（电子版）

摘　　要：Long-term antiviral treatment of chronic hepatitis B patients has been proven to be beneficial in reducing liver-related complications.However,lengthy periods of daily administration of medication have some inevitable drawbacks,including decreased medication adherence,increased cost of treatment,and possible longterm side effects.Currently,discontinuation of antiviral agent has become the strategy of interest to many hepatologists,as it might alleviate the aforementioned drawbacks and increase the probability of achieving functional cure.This review focuses on the current evidence of the outcomes following stopping antiviral treatment and the factors associated with subsequent hepatitis B virus relapse,hepatitis B surface antigen clearance,and unmet needs.

关 键 词：Viral hepatitis B RELAPSE RETREATMENT SCALE-B Stop treatment strategy Nucleoside analogs 

分 类 号：R512.62[医药卫生—内科学]